drugset

drugset / Trial / NCT04052191

MCRcI® Stem Cell Treatment for Diffuse Coronary Artery Disease

NCT04052191 ↗

Phase 1 Not yet recruiting 40 enrolled Honya Medical Inc Chang Gung Memorial Hospital · collab

RandomizedSequentialSingle-blindTreatment

Summary

Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.

Timeline

Start: 2025-12-01
Primary completion: 2026-01-01
Completion: 2026-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MCRcI®	Cell therapy	—	Other

Indications